Nanoscale Res Lett 2009, 4:982–992 10 1007/s11671-009-9345-3Cros

Nanoscale Res Lett 2009, 4:982–992. 10.1007/s11671-009-9345-3CrossRef 19. Romberg B, Hennink WE, Storm G: Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25:55–71. 10.1007/s11095-007-9348-7CrossRef 20. Roberts MJ, Bentley MD, Harris JM: Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002, 54:459–476. 10.1016/S0169-409X(02)00022-4CrossRef 21. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG: The influence of PEG

chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011, 32:6791–6803. 10.1016/j.biomaterials.2011.04.082CrossRef 22. Chun KW, Yoo HS, Yoon JJ, Park TG: Biodegradable PLGA microcarriers for injectable delivery of chondrocytes: effect of surface modification on cell attachment and function. Biotechnol Prog 2004, selleck screening library 20:1797–1801. 10.1021/bp0496981CrossRef 23. Even-Chen S, Barenholz

Y: DOTAP Selleck JQEZ5 cationic liposomes prefer relaxed over supercoiled plasmids. Biochim Biophys Acta 2000, 1509:176–188. 10.1016/S0005-2736(00)00292-3CrossRef 24. Cai Q, Shi G, Bei J, Wang S: Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin. Biomaterials 2003, 24:629–638. 10.1016/S0142-9612(02)00377-0CrossRef 25. Hamdy S, Haddadi A, Hung RW, Lavasanifar A: Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011, 63:943–955. 10.1016/j.addr.2011.05.021CrossRef 26. Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG: Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 2012, 509:143–163.CrossRef Competing interests The authors declare

that they have no competing interests. Authors’ contributions YH carried out the experiments and drafted the manuscript. ME participated in the design of the experiments. KF participated in the experiments related to dendritic cell culture. CZ conceived the study, participated in its design and coordination, and revised the manuscript. All authors read and approved the final manuscript.”
“Background Interests on semiconductor nanowires (NWs) are derived from their CYT387 in vitro unique physical properties compared with the bulk materials such as the quantum confinement and increased cross sections ifenprodil [1, 2] as well as their potentials to be adapted in numerous electronic, optoelectronic, and nanomechanic applications [3–5]. For instance, a single GaAs NW photovoltaic device has demonstrated 40% conversion efficiency over the ‘Shockley-Queisser limit’ [5]. The fabrication of NWs is usually achieved via the metallic droplet-assisted vapor-liquid-solid (VLS) mechanism [6–8]. In the VLS, crystallization can occur at the liquid-solid interface due to the higher sticking coefficient and the Au droplets as a common catalyst exert an excellent capability of transferring the vapor phase precursors through the supersaturation regardless of the materials and substrates utilized.

Related posts:

  1. PubMedCrossRef 19 Smythe AB, Sanderson MJ, Nadler SA: Nematode s
  2. Taken together, results of the current and previous studies demon
  3. , 2009) Intracellular bioactivity in such scenarios can, however
  4. Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
  5. Spring Harbor Laboratory Press, Cold Spring Harbor,

    NY; 1
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>